ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 235,11
0,78%
Dow Jones
44 910,65
0,42%
DAX
19 626,45
1,05%
Brent Oil
71,98
0,00%
Bitcoin
96 181,93
-0,26%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. CRISPR Therapeutics AG (CRSP)

  7. CRISPR Therapeutics AG (CRSP) Actualités

CRSP

CRISPR Therapeutics (CRSP)

CRISPR Therapeutics AG
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CRSP
DateHeureSourceTitreSymboleSociété
14/11/202414h30GlobeNewswire Inc.CRISPR Therapeutics to Present at the Jefferies London Healthcare ConferenceNASDAQ:CRSPCRISPR Therapeutics AG
13/11/202423h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRSPCRISPR Therapeutics AG
07/11/202414h00GlobeNewswire Inc.CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation ConferenceNASDAQ:CRSPCRISPR Therapeutics AG
05/11/202415h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRSPCRISPR Therapeutics AG
05/11/202415h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRSPCRISPR Therapeutics AG
05/11/202415h01GlobeNewswire Inc.CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:CRSPCRISPR Therapeutics AG
05/08/202423h22Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:CRSPCRISPR Therapeutics AG
05/08/202422h54Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CRSPCRISPR Therapeutics AG
05/08/202422h01GlobeNewswire Inc.CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:CRSPCRISPR Therapeutics AG
30/05/202422h26Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CRSPCRISPR Therapeutics AG
29/05/202414h00GlobeNewswire Inc.CRISPR Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:CRSPCRISPR Therapeutics AG
23/05/202414h00GlobeNewswire Inc.CRISPR Therapeutics Strengthens Executive Leadership Team with Key AppointmentsNASDAQ:CRSPCRISPR Therapeutics AG
09/05/202414h30GlobeNewswire Inc.CRISPR Therapeutics to Present at the Bank of America Securities Health Care ConferenceNASDAQ:CRSPCRISPR Therapeutics AG
08/05/202422h00GlobeNewswire Inc.CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:CRSPCRISPR Therapeutics AG
08/05/202413h00GlobeNewswire Inc.CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing ApproachNASDAQ:CRSPCRISPR Therapeutics AG
22/04/202422h30GlobeNewswire Inc.CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual MeetingNASDAQ:CRSPCRISPR Therapeutics AG
03/04/202414h00GlobeNewswire Inc.CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare ConferenceNASDAQ:CRSPCRISPR Therapeutics AG
01/04/202414h00GlobeNewswire Inc.CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual MeetingNASDAQ:CRSPCRISPR Therapeutics AG
13/03/202413h30GlobeNewswire Inc.CRISPR Therapeutics Proposes New Appointment to the Board of DirectorsNASDAQ:CRSPCRISPR Therapeutics AG
21/02/202413h50Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CRSPCRISPR Therapeutics AG
21/02/202413h30GlobeNewswire Inc.CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CRSPCRISPR Therapeutics AG
15/02/202422h30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CRSPCRISPR Therapeutics AG
15/02/202414h30GlobeNewswire Inc.CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership SummitNASDAQ:CRSPCRISPR Therapeutics AG
13/02/202414h44Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CRSPCRISPR Therapeutics AG
13/02/202414h30GlobeNewswire Inc.CRISPR Therapeutics Announces $280 Million Registered Direct OfferingNASDAQ:CRSPCRISPR Therapeutics AG
13/02/202408h30GlobeNewswire Inc.European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)NASDAQ:CRSPCRISPR Therapeutics AG
29/01/202422h00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CRSPCRISPR Therapeutics AG
16/01/202422h01GlobeNewswire Inc.CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta ThalassemiaNASDAQ:CRSPCRISPR Therapeutics AG
08/01/202413h00GlobeNewswire Inc.CRISPR Therapeutics Highlights Strategic Priorities and 2024 OutlookNASDAQ:CRSPCRISPR Therapeutics AG
03/01/202414h30GlobeNewswire Inc.CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:CRSPCRISPR Therapeutics AG
 Showing the most relevant articles for your search:NASDAQ:CRSP

Dernières Valeurs Consultées

LSE
33JE
Barclays Nts45
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés

BLACK FRIDAY

ADVFN

Célébrons nos 25 ans Est 1999-2024

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Cours Euronext en temps réel et illimités sur le site. Carnet d'ordres Euronext en direct